Fosun Pharma raises $512 million, while Dynasty Reit cancels IPO

The market remains challenging for new listings and both deals attract modest demand from international investors, with Fosun forced to reallocate shares to retail investors to make up for the lack of institutional interest.
<div style="text-align: left;">
Fosun's Shanghai headquarters
</div>
<div style="text-align: left;"> Fosun's Shanghai headquarters </div>

Shanghai Fosun Pharmaceutical has raised HK$3.97 billion ($512 million) after pricing its Hong Kong initial public offering at the bottom of the indicated range.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media